ltrafast immunotherapy in allergic rhinitis
Phase 3
- Conditions
- Perennial allergic rhinitis.Perennial allergic rhinitis
- Registration Number
- IRCT2017010123235N8
- Lead Sponsor
- Vice chancellor for research, Mashhad University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 21
Inclusion Criteria
The risk of perennial allergic rhinitis; Positive skin test to allergens in the air; Clinical signs associated with skin test
Exclusion criteria: History of autoimmune disease; Patients with systemic corticosteroids or immunosuppressive drugs for reasons other than allergic disease on the immune system use to be effective; Pregnancy; Immunocompromised patients, patients who have uncontrolled allergic asthma; Patients with malnutrition; Patients who received beta-blocker drugs; Patients with a history of anaphylaxis; patients With coexisting cardiovascular disease; During treatment, patients who are experiencing systemic reactions; Patients with mental disorders
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Clinical symptoms. Timepoint: Befor the trial. Method of measurement: questionnaire.
- Secondary Outcome Measures
Name Time Method FOXP3. Timepoint: 3 month later. Method of measurement: Flowcytometry.;IFN-?. Timepoint: 3 month later. Method of measurement: Flowcytometry.;IL-4. Timepoint: 3 month later. Method of measurement: Flowcytometry.